Is it appropriate for an 80-year-old patient to take quetiapine (Seroquel) 25 mg twice daily?

Quetiapine 25mg Twice Daily in an 80-Year-Old: Inappropriate Dosing

This dosing regimen is inappropriate for an 80-year-old patient. The FDA label explicitly states that elderly patients should be started on 50 mg/day (not 50 mg/day divided into two doses, but 50 mg total daily dose) with slower titration in increments of 50 mg/day 1. The current regimen of 25 mg twice daily totals 50 mg/day, which appears correct at first glance, but the critical issue is the indication and appropriateness of antipsychotic use in this elderly patient.

Primary Concerns

Beers Criteria and Mortality Risk

The 2019 AGS Beers Criteria strongly recommends avoiding antipsychotics in older adults due to increased mortality risk 2. This is a strong recommendation with high-quality evidence. Antipsychotics should be avoided unless treating approved psychiatric conditions (schizophrenia, bipolar disorder) where benefits clearly outweigh risks.

Recent Safety Data

A 2025 study demonstrated that low-dose quetiapine for insomnia in older adults significantly increases:

• All-cause mortality (HR 3.1 vs. trazodone) 3
• Dementia risk (HR 8.1 vs. trazodone; HR 7.1 vs. mirtazapine) 3
• Falls (HR 2.8 vs. trazodone) 3

This is the most recent, high-quality evidence directly addressing low-dose quetiapine safety in elderly patients and should guide clinical decision-making.

Clinical Decision Algorithm

Step 1: Determine the indication

• If prescribed for approved indications (schizophrenia, bipolar disorder):

  • The 50 mg/day total dose is appropriate as a starting dose 1
  • Monitor closely for hypotension, dizziness, and somnolence (most common adverse effects in elderly) 4, 5
  • Titrate slowly in 50 mg/day increments based on response 1

• If prescribed for off-label use (insomnia, agitation, behavioral symptoms):

  • Discontinue quetiapine 2, 3
  • Consider safer alternatives (trazodone, mirtazapine for insomnia) 3
  • Address underlying causes of symptoms

Step 2: Assess for contraindications

• Dementia: Antipsychotics carry black box warning for increased mortality 2
• Cardiovascular disease: Monitor for hypotension (15% incidence in elderly) 5
• Concurrent medications: Check for CYP3A4 inhibitors requiring dose reduction to 1/6 of current dose 1

Step 3: Pharmacokinetic considerations Elderly patients (≥70 years) have 67% higher serum concentrations of quetiapine compared to younger adults 6. This supports the FDA's recommendation for lower starting doses and slower titration.

Critical Pitfalls

1. Off-label prescribing: 79% of exploratory studies suggesting quetiapine efficacy for off-label indications were never confirmed by large randomized trials 7. This drug is widely misprescribed for conditions lacking evidence.

2. Underestimating mortality risk: Even at low doses (25-75 mg/day), quetiapine significantly increases mortality in elderly patients 3. The "low dose is safer" assumption is not supported by evidence.

3. Ignoring alternatives: For insomnia specifically, trazodone and mirtazapine have superior safety profiles in elderly patients 3.

Monitoring Requirements if Continuation is Necessary

If quetiapine must be continued for an approved indication:

• Blood pressure monitoring (orthostatic hypotension risk)
• Fall risk assessment
• Cognitive function monitoring
• Periodic reassessment of continued need 1
• EPS monitoring (though risk is lower with quetiapine than typical antipsychotics) 5

The dose itself may be technically correct per FDA labeling, but the appropriateness depends entirely on the indication. For off-label uses, particularly insomnia, this medication should be discontinued given the substantial mortality and morbidity risks in this age group 2, 3.